Literature DB >> 10441464

Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP.

J Kotera1, K Fujishige, K Yuasa, K Omori.   

Abstract

We have isolated a novel alternative splice variant of human cAMP- and cGMP-hydrolyzing phosphodiesterase (PDE10A2) from human fetal lung. The N-terminal sequence of human PDE10A2 differed from that of human PDE10A1 reported previously. PDE10A1 and PDE10A2 expressed in COS-7 cells have cGMP K(m) values of 14 and 13 microM, low cAMP K(m) values of 0.28 and 0.22 microM, and high cAMP K(m) values of 0.96 and 1.1 microM, respectively, at high concentrations of cGMP and cAMP. PCR analysis demonstrated that both PDE10A1 and PDE10A2 transcripts are present in various human tissues and that PDE10A2 transcripts are a major form in some human tissues. The unique N-terminus of PDE10A2 has a putative phosphorylation site by cAMP-dependent protein kinase (cAK), but PDE10A1 does not. The recombinant PDE10A2 protein is preferentially phosphorylated by cAK, although the recombinant PDE10A1 protein is not phosphorylated by cAK. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441464     DOI: 10.1006/bbrc.1999.1013

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Authors:  Hui Liu; Hongjun Jin; Zonghua Luo; Xuyi Yue; Xiang Zhang; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

3.  Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.

Authors:  Zhanbin Zhang; Xiaoxia Lu; Jinbin Xu; Justin Rothfuss; Robert H Mach; Zhude Tu
Journal:  Eur J Med Chem       Date:  2011-06-12       Impact factor: 6.514

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

5.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

Review 6.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.

Authors:  Kevin Lee; Ashley S Lindsey; Nan Li; Bernard Gary; Joel Andrews; Adam B Keeton; Gary A Piazza
Journal:  Oncotarget       Date:  2016-02-02

8.  Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder.

Authors:  C M MacMullen; K Vick; R Pacifico; M Fallahi-Sichani; R L Davis
Journal:  Transl Psychiatry       Date:  2016-02-23       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.